Skip to main content
OpenTrials
Completed

NCT Number: NCT02191280

Antistax® in Patients With Chronic Venous Insufficiency

Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • Between 25 and 75 years of age
  • CVI I or CVI II (without expanded trophic disturbances)
  • Willing and able to give written informed consent prior to participation in the study

Exclusion criteria

Concomitant disease(s) exclusion criteria:

  • Decompensated cardiac insufficiency
  • Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
  • Peripheral arterial disease (ankle/arm pressure index < 0.9)
  • Current acute phlebitis or thrombosis
  • Renal insufficiency (Serum creatinine > 1.5 mg/dl)
  • Liver disease (SGPT (ALAT) > 3x upper limit of normal)
  • Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
  • Anamnestic indications of diabetic microangiopathy or polyneuropathy
  • Drug and/or alcohol abuse
  • Severe climacteric complaints
  • Immobility
  • Avalvulia
  • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
  • State after pulmonary embolism
  • Recognized hypersensitivity to the trial drug ingredients
  • Current florid venous ulcus
  • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.

Previous treatment(s) exclusion criteria:

  • Treatment with venous drugs within the last 4 weeks
  • Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
  • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
  • Changes in post-menopausal Hormone replacement within the last 2 months

Concomitant treatment/non-drug therapy exclusion criteria:

  • Other venous drugs apart from the trial medication
  • Compression therapy
  • Venous surgery at the leg(s)
  • Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
  • Major surgery requiring full anesthesia

Other exclusion criteria:

  • Previously studied under this protocol
  • Participation in another clinical trial within the previous 90 days or during the present study
  • Patients who have visited a sauna or had other thermal applications in the previous day before any visit
  • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
  • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  • Patients in a bad general health state according to the investigator's judgment

Treatment and study plan

Antistax®, low dose

Drug

Antistax®, high dose

Drug

Placebo

Drug

Primary outcomes

  1. Changes from baseline of limb volume

    Time frame: Baseline, day 84

    determined by water displacement

Secondary outcomes

  1. Changes of limb volume

    Time frame: Baseline, days 42 and 98

    determined by water displacement

  2. Measurement of calf circumference

    Time frame: Baseline, days 42, 84 and 98

    in centimeters

  3. Measurement of ankle circumference

    Time frame: Baseline, days 42, 84 and 98

    in centimeters

  4. Assessment of subjective symptoms on a visual analogue scale (VAS)

    Time frame: Baseline, days 42, 84 and 98

  5. Assessment of global efficacy by patient on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  6. Assessment of global efficacy by investigator on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  7. Assessment of global tolerability by patient on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  8. Assessment of global tolerability by investigator on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  9. Number of patients with adverse events

    Time frame: up to 14 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study

Important dates

Study start
1998
Primary completion
1998
First posted
Jul 16, 2014
Registry last updated
Jul 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.